Interviews

Dr Richard Snyder on the Impact of Novel, Costly Drugs on Prevalence of Value-Based Agreements
October 15, 2019 – 
Richard Snyder, MD, executive vice president of Facilitated Health Networks and chief medical officer at Independence Blue Cross, discusses how the increasing share of novel, costly therapies will impact the prevalence of value-based agreements.
Dr Jeff Patton on What Comes After the OCM
October 15, 2019 – 
Jeff Patton, MD, chief executive officer of Tennessee Oncology, discusses if there's concern over what comes when the Oncology Care Model (OCM) ends.
Tesh Khullar: How Community Oncologists Can Get Ahead of Changes in Reimbursement for Biosimilars
October 15, 2019 – 
Practices are going to have to decide which biosimilar manufacturers they want to be able to partner with, explained Tesh Khullar, senior vice president & advisor, Flatiron Health.
Erich Mounce: Partnerships and Performance Data Can Initiate Sustainable Growth in Clinical Practice
October 14, 2019 – 
Initiating sustainable growth in clinical practices can be difficult, but through economies of scale derived from partnerships and performance data collection, optimal care can be administered efficiently, said Erich Mounce, chief operating officer, OneOncology.
Dr Prithviraj Bose Discusses Identifying Progression in Myelofibrosis
October 14, 2019 – 
There are formal criteria to identify progression in myelofibrosis, but patients can progress in many different ways, said Prithviraj Bose, MD, of MD Anderson Cancer Center.
Dr Jan Hillert Addresses Stem Cell Transplants in Treating MS
October 14, 2019 – 
Jan Hillert, MD, PhD, professor and senior physician in the department of clinical neuroscience, Karolinska Institutet, Stockholm, Sweden, discusses the body of knowledge on using stem cell transplants to treat patients with multiple sclerosis (MS).
 
Dr Amila Patel: How Flatiron's Clinical Workflow Efforts Will Expand Beyond EHRs
October 13, 2019 – 
Amila Patel, PharmD, BCOP, technical lead, Clinical Oncology, Flatiron Health, discusses how Flatiron is working to implement clinical workflow features that expand beyond the electronic health record (EHR).
Dr Steven R. Feldman on the Effect of Metabolic Syndrome on Treatments for Psoriasis
October 12, 2019 – 
Steven R. Feldman, MD, PhD, professor of dermatology, Wake Forest School of Medicine, discusses how some drugs for psoriasis are less effective in the presence of metabolic syndrome.
Bobby Green: Artificial Intelligence, Machine Learning Critical to Growth in Effective Healthcare
October 11, 2019 – 
Utilizing, and expanding upon, available technology in medical practices can efficiently improve healthcare, said Bobby Green, MD, chief medical officer at Flatiron.
Dr Ebtesam Alshehri Discusses Smoking and MS Disease Progression
October 11, 2019 – 
Ebtesam Alshehri, MD, neurologist, Cleveland Clinic, explains what patients with multiple sclerosis (MS) should know about the impact of smoking on disease progression.
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.